A photosensitizer for near-infrared fluorescence imaging-guided photodynamic and photothermal therapy and its preparation and application
By designing and preparing photosensitizers BTBT, NTBT and ATBT as electron donors for benzene, naphthalene and anthracene, the existing photodynamic and photothermal treatment nanoparticles are solved, and efficient reactive oxygen generation and photothermal conversion are achieved. , suitable for near-infrared fluorescence imaging-guided tumor treatment, has multimodal photodiagnosis and treatment performance and good biosafety.
Patent Information
- Application Number
- CN202410439403.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-12
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-04-12
AI Technical Summary
The existing photodynamic and photothermal treatment nanoparticles have insufficient 1O2 generation and low photothermal conversion efficiency in functional, and have poor repeatability, which makes it difficult to apply in clinical environments, lack specific theoretical and structural design guidance, and design balanced design Single-component organic photosensitizers have great challenges.
Photosensitizers BTBT, NTBT and ATBT with benzene, naphthalene and anthracene as electron donors were designed and prepared. The fluorescence emission, reactive oxygen generation and photothermal conversion capabilities were optimized through intramolecular charge transfer and intramolecular free rotation, and nanoprecipitation was used. Methods were used to prepare nanoparticles with good water-soluble properties for photodynamic-photothermal therapy guided by near-infrared fluorescence imaging.
It has achieved efficient generation of reactive oxygen species and excellent photothermal conversion efficiency under 660nm laser radiation, and has multimodal photodiagnosis and treatment performance. It is suitable for integrated tumor diagnosis and treatment, especially for the treatment of superficial subcutaneous tumors, and has shown good results. biosafety and metabolic clearance.
Smart Images

Figure CN118307561B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical materials, and in particular relates to a photosensitizer for photodynamic and photothermal therapy guided by near-infrared fluorescence imaging, and a preparation and application thereof. Background Art
[0002] The combination of PDT (photodynamic therapy) and PTT (photothermal therapy) has been shown to be a very effective tumor treatment strategy, which can effectively compensate for their respective limitations and give full play to the advantages of combined therapy. Reactive oxygen species (ROS)-mediated PDT can damage heat shock proteins, which helps to improve the anti-tumor effect of PTT. On the other hand, PTT can ablate tumors regardless of oxygen levels. In addition, it can enhance blood circulation by generating heat, thereby increasing the oxygen content in hypoxic tumor tissues, thereby improving the therapeutic effect of PDT. Therefore, the respective deficiencies of PDT and PTT can be balanced through synergy, thereby achieving the effect of "1+1>2".
[0003] As two energy consumption modes of non-radiative transition, PDT promoted by intersystem crossing and PTT caused by thermal inactivation are essentially in a competitive relationship. In order to achieve combined therapy, many phototherapy agents currently use an "all-in-one" strategy, that is, assembling components with different functions into the same nanoparticle. However, in terms of function, these nanoparticles may still face 1 Problems such as insufficient O2 generation and low photothermal conversion efficiency. More importantly, the poor reproducibility and unclear pharmacokinetics of these nanoparticles make it difficult to apply them in clinical settings. Due to the lack of specific theoretical and structural design guidance, the design and synthesis of single-component organic photosensitizers with balanced PDT and PTT performances remains challenging. Summary of the invention
[0004] The purpose of the present invention is to provide a photosensitizer for photodynamic and photothermal therapy guided by near-infrared fluorescence imaging to solve the problems existing in the prior art.
[0005] A photosensitizer for near-infrared fluorescence imaging-guided photodynamic and photothermal therapy, with the following structural formula:
[0006]
[0007] The present invention uses benzene, naphthalene and anthracene as electron donors to design and prepare a series of photosensitizers BTBT, NTBT and ATBT, which can be used as single-component organic photosensitizers for near-infrared fluorescence imaging-guided photodynamic-photothermal therapy. Among them, the photosensitizer BTBT using a benzene ring as a donor has a strong intramolecular charge transfer and a flatter main structure, showing optimal fluorescence emission, reactive oxygen generation and photothermal conversion capabilities, which is conducive to the realization of multimodal photodiagnosis and treatment. First, BTBT has the strongest intramolecular charge transfer properties, which gives it the smallest HOMO-LUMO energy system (ΔE L-H );ΔE L-H The smaller the value, the longer the emission wavelength of the photosensitizer, so BTBT has the longest fluorescence emission wavelength; secondly, BTBT has a smaller singlet-triplet energy gap (ΔE S-T ) and a higher self-selected orbital coupling constant (SOC), which is conducive to its intersystem crossing (ISC) to produce reactive oxygen species and be used for photodynamic therapy; finally, BTBT's relatively flat molecular configuration and stronger intramolecular free rotation enable it to exhibit the best photothermal conversion performance.
[0008] The preparation method of the above-mentioned photosensitizer comprises the following steps:
[0009] (1) adding bromothienylthiadiazolebenzotriazole, phenylboric acid or naphthaleneboric acid or anthraceneboric acid, tetrakis(triphenylphosphine)palladium and potassium carbonate to a solvent;
[0010] (2) reflux the mixed solution at 60-100° C. for 10-24 hours;
[0011] (3) After the reaction is completed, the mixture is washed and the solvent is removed, followed by column chromatography purification.
[0012] Furthermore, the molar ratio of the added bromothienylthiadiazolebenzotriazole, phenylboric acid or naphthaleneboric acid or anthraceneboric acid is 1:2-5.
[0013] Furthermore, the solvent is a mixed solvent of tetrahydrofuran and water.
[0014] Furthermore, the method further comprises step (4): adding the amphiphilic organic polymer solution and the photosensitizer obtained in step (3) into deionized water at a weight ratio of 3-8:1, ultrasonicating at 50% output power, stirring for 1-2 hours, and purifying using an ultrafiltration centrifuge tube.
[0015] Furthermore, the amphiphilic organic polymer is a PEG series polymer or a polyoxypropylene-polyoxyethylene copolymer.
[0016] Application of the above photosensitizer in the preparation of tumor treatment preparations.
[0017] The above photosensitizer is used in the preparation of photodynamic and photothermal combined therapy preparations.
[0018] A tumor diagnosis and treatment integrated preparation, comprising the above-mentioned photosensitizer.
[0019] Compared with the prior art, the present invention uses benzene, naphthalene and anthracene as electron donors to design and prepare a series of photosensitizers BTBT, NTBT and ATBT, which can not only generate a large amount of reactive oxygen species under the irradiation of 660nm laser, but also have extremely high photothermal conversion efficiency; the inherent near-infrared fluorescence emission of the photosensitizer of the present invention is conducive to photodynamic-photothermal synergistic therapy guided by near-infrared fluorescence imaging, can be used for integrated tumor diagnosis and treatment, and is suitable for the treatment of subcutaneous superficial tumors. The present invention realizes photodynamic-photothermal regulation by changing the electron donating ability of the donor and the free rotation within the molecule, which can not only enhance photodynamics, but also promote photothermal conversion efficiency. The photosensitizer BTBT of the present invention using a benzene ring as a donor exhibits optimal fluorescence emission, reactive oxygen generation and photothermal conversion capabilities, which is conducive to the realization of multimodal photodiagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 are the structural formulas of three photosensitizers of the present invention;
[0021] Figure 2 Schematic diagram of the preparation of three photosensitizers of the present invention;
[0022] Figure 3 (a) is the ultraviolet absorption spectrum of the photosensitizer of the present invention; (b) is the normalized fluorescence spectrum of the photosensitizer of the present invention;
[0023] Figure 4 The photosensitizer of the present invention has an optimized molecular structure, electronic orbital arrangement, singlet-triplet energy gap and self-selected orbital coupling constant;
[0024] Figure 5 The morphology and particle size of the nanoparticles of the photosensitizer of the present invention;
[0025] Figure 6 (a) is the ultraviolet absorption spectrum of the photosensitizer nanoparticles of the present invention; (b) is the fluorescence spectrum of the photosensitizer nanoparticles of the present invention;
[0026] Figure 7 (a) is the total reactive oxygen species generating capacity of ATBT nanoparticles; (b) is the total reactive oxygen species generating capacity of NTBT nanoparticles; (c) is the total reactive oxygen species generating capacity of BTBT nanoparticles; (d) is the reactive oxygen species identifying BTBT NPs by ABDA; (e) is the reactive oxygen species identifying BTBT NPs by HPF; (f) is the reactive oxygen species identifying BTBT NPs by DHR123;
[0027] Figure 8 (a) is the temperature change of ATBT, NTBT and BTBT nanoparticle solutions with laser irradiation time; (b) is the concentration dependence of the temperature change of BTBT nanoparticle solution; (c) is the power dependence of the temperature change of BTBT nanoparticle solution; (d) is the photothermal stability of BTBT nanoparticle solution; (e) is the photothermal conversion efficiency of BTBT nanoparticle solution; (f) is the change of photoacoustic signal intensity of BTBT nanoparticles with concentration;
[0028] Fig. 9 is the molecular structure of ATBT, NTBT and BTBT in S1 state, and the changes of corresponding dihedral angles;
[0029] Fig.10 It is near-infrared fluorescence imaging to monitor the changes of fluorescence signals at the tumor position of tumor-bearing mice over time;
[0030] Fig.11 This is the metabolism of BTBT nanoparticles in the blood and major organs; 1-heart; 2-liver; 3-spleen; 4-lung; 5-kidney; 6-stomach; 7-intestine; 8-tumor. DETAILED DESCRIPTION
[0031] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.
[0032] Example 1
[0033] A method for preparing a photosensitizer BTBT for near-infrared fluorescence imaging-guided photodynamic and photothermal therapy, such as Figure 2 As shown, the following steps are included:
[0034] Under an argon atmosphere, compound 1 (bromothienylthiadiazolebenzotriazole) (6 mmol), phenylboric acid (14 mmol), tetrakis(triphenylphosphine)palladium (0.30 mmol) and potassium carbonate (36 mmol) were added to a mixed solvent of tetrahydrofuran (40 mL) and water (10 mL); the mixed solution was refluxed at 60-100°C for 10-24 hours; after the reaction was completed, the mixture was washed and the solvent was removed, and then purified by column chromatography to obtain BTBT.
[0035] Since the water solubility of organic photosensitizers is poor, the hydrophobic organic photosensitizer BTBT is encapsulated by the amphiphilic polymer DSPE-SS-mPEG5000 in this embodiment, and BTBT nanoparticles (NPs) with good water solubility are prepared by nanoprecipitation. The specific method is as follows: 1mL of tetrahydrofuran solution containing 1mg BTBT and 5mg DSPE-SS-mPEG5000 is poured into 9mL of deionized water. The solution is ultrasonically treated at 50% output power for 1 minute, then stirred for 2 hours and purified with an ultrafiltration centrifuge tube to obtain BTBT NPs.
[0036] Example 2
[0037] A method for preparing a photosensitizer NTBT for near-infrared fluorescence imaging-guided photodynamic and photothermal therapy, such as Figure 2 As shown, the following steps are included:
[0038] Under an argon atmosphere, compound 1 (bromothienylthiadiazolebenzotriazole) (6 mmol), naphthaleneboric acid (14 mmol), tetrakis(triphenylphosphine)palladium (0.30 mmol) and potassium carbonate (36 mmol) were added to a mixed solvent of tetrahydrofuran (40 mL) and water (10 mL); the mixed solution was refluxed at 60-100°C for 10-24 hours; after the reaction was completed, the mixture was washed and the solvent was removed, and then purified by column chromatography to obtain NTBT.
[0039] Since the water solubility of organic photosensitizers is poor, the hydrophobic organic photosensitizer NTBT is encapsulated by the amphiphilic polymer DSPE-SS-mPEG5000 in this embodiment, and NTBT nanoparticles (NPs) with good water solubility are prepared by nanoprecipitation. The specific method is as follows: 1mL of tetrahydrofuran solution containing 1mg NTBT and 5mg DSPE-SS-mPEG5000 is poured into 9mL of deionized water. The solution is ultrasonically treated at 50% output power for 1 minute, then stirred for 2 hours and purified with an ultrafiltration centrifuge tube to obtain NTBT NPs.
[0040] Example 3
[0041] A method for preparing a photosensitizer ATBT for near-infrared fluorescence imaging-guided photodynamic and photothermal therapy, such as Figure 2 As shown, the following steps are included:
[0042] Under an argon atmosphere, compound 1 (bromothienylthiadiazolebenzotriazole) (6 mmol), anthraceneboric acid (14 mmol), tetrakis(triphenylphosphine)palladium (0.30 mmol) and potassium carbonate (36 mmol) were added to a mixed solvent of tetrahydrofuran (40 mL) and water (10 mL); the mixed solution was refluxed at 60-100°C for 10-24 hours; after the reaction was completed, the mixture was washed and the solvent was removed, and then purified by column chromatography to obtain ATBT.
[0043] Since the water solubility of organic photosensitizers is poor, the hydrophobic organic photosensitizer ATBT is encapsulated by the amphiphilic polymer DSPE-SS-mPEG5000 in this embodiment, and ATBT nanoparticles (NPs) with good water solubility are prepared by nanoprecipitation. The specific method is as follows: 1 mL of tetrahydrofuran solution containing 1 mg ATBT and 5 mg DSPE-SS-mPEG5000 is poured into 9 mL of deionized water. The solution is ultrasonically treated at 50% output power for 1 minute, then stirred for 2 hours and purified with an ultrafiltration centrifuge tube to obtain ATBT NPs.
[0044] Performance Test:
[0045] 1. Optical properties
[0046] First, the photophysical properties of the organic photosensitizers (PSs) ATBT, NTBT and BTBT prepared in Examples 1-3 were investigated using UV-visible absorption spectra and fluorescence emission spectra. Figure 3 As shown in (a), the maximum absorption peaks of the three PSs in CH2Cl2 solution are 644, 656 and 676 nm, respectively, and all show high molar extinction coefficients, which are located at 3.0×10 4 -3.8×10 4 M -1 cm -1 In addition, from Figure 3 As can be seen in (b), the maximum emission wavelengths of ATBT, NTBT and BTBT solutions are at 752, 772 and 780 nm, respectively, all located in the near-infrared 1 region, showing great potential for fluorescence imaging.
[0047] 2. Theoretical calculation
[0048] In order to further understand the photophysical and photochemical properties of ATBT, NTBT and BTBT prepared in Examples 1-3, DFT and TD-DFT theoretical calculations were performed using the Gauss16 program. First, the optimal structure of PSs in the ground state and the corresponding electron orbital distribution were calculated at the B3LYP / 6-31G** level. Figure 4From the optimized geometric structure, it can be seen that the dihedral angles between the electron-withdrawing unit and the π-bridge in the three photosensitizers are close to 180°, while the dihedral angles between the electron-donating unit and the π-bridge are very different. The angle between the electron-donating part and thiophene in ATBT is almost a right angle, which is much larger than 47° in NTBT and 26° in BTBT. Calculations show that the molecular structure of BTBT has the highest flatness, so its molar extinction coefficient is the largest. In addition, the electrons in the HOMO orbitals of the three photosensitizers are mainly distributed on the electron-donating unit and the π-bridge, while the electrons in the LUMO orbitals are mainly concentrated on the electron-withdrawing group in the middle, further proving the inherent intramolecular charge transfer properties of PSs themselves. Figure 4 As shown in Figure 2, with the enhancement of the electron donation and withdrawal ability of PSs, the separation between the HOMO and LUMO orbitals of BTBT is most obvious, and the ΔE L-H The values of ΔE and ΔE are 1.91, 1.77 and 1.72 eV respectively. L-H , so BTBT exhibits the longest fluorescence emission wavelength.
[0049] Perturbation theory shows that the reduction in electron exchange energy and the highly separated charge distribution lead to a small singlet-triplet energy gap (ΔE S-T ), which is conducive to accelerating the intersystem crossing (ISC) process. On this basis, the present invention also calculated the ΔE of PSs S-T .like Figure 4 As shown, the ΔE of ATBT, NTBT and BTBT S-T The SOC of the three PSs is 0.017, 0.005 and 0.018 cm-1, respectively. -1 Efficient ISC is beneficial for PDT and thus has a smaller ΔE S-T BTBT with higher SOC is expected to have excellent PDT performance.
[0050] 3. Preparation of nanoparticles and their optical properties
[0051] The water-soluble nanoparticles (NPs) prepared by the nanoprecipitation method of the present invention all exhibit good water dispersibility. Figure 5 As shown, transmission electron microscopy confirmed that the ATBT NPs, NTBT NPs and BTBT NPs prepared in Examples 1-3 all had a uniform spherical morphology, and the diameters were all 50-100 nm.
[0052] The present invention further explores the optical properties of ATBT NPs, NTBT NPs and BTBT NPs. Figure 6As shown in (a), the absorption wavelengths of the three nanoparticles are mainly concentrated in 500-800nm, which is similar to the absorption band of the solution and is located in the near-infrared region (NIR-I). Among them, the extinction molar coefficient of BTBT NPs is the largest, which is conducive to fully absorbing light energy. Figure 6 The fluorescence spectra in (b) demonstrate that the fluorescence emission wavelengths of the three nanoparticles are all located in the NIR-I region, reaching peaks at 772, 761, and 768 nm, respectively, showing great potential for in vivo NIR fluorescence imaging.
[0053] 4. In vitro photodynamic performance
[0054] In order to further detect the photodynamic activity of NPs, the present invention uses DCFH to evaluate the total ROS generation performance of NPs. Figure 7 As shown, after DCFH was mixed with ATBT NPs, NTBT NPs and BTBT NPs, the fluorescence intensity gradually increased within 5 minutes of irradiation. In particular, in the presence of BTBT NPs, the fluorescence intensity of DCFH reached more than 37 times that of the initial state within 5 minutes, which means that BTBT NPs have excellent ROS generation ability. Further, the present invention uses ABDA, HPF and DHR123 to identify the types of reactive oxygen species. Figure 7 As shown in the figure, after 5 minutes of laser irradiation, the absorption intensity of ABDA decreased slightly, indicating that a small amount of singlet oxygen was generated. The fluorescence intensity of HPF and DHR123 increased significantly with the extension of irradiation time, indicating that BTBT NPs can also generate hydroxyl radicals and superoxide radicals.
[0055] 5. Study on the performance and mechanism of in vitro photothermal therapy
[0056] In view of the excellent light absorption performance of the three nanoparticles, the present invention further tests their photothermal conversion performance. Figure 8 As shown in (a), (b), and (c), the temperature of the aqueous solution of the three nanoparticles gradually increased during the 3-minute irradiation time. Among them, BTBT NPs has the best photothermal conversion performance, and the temperature can rise to more than 64°C within 3 minutes. Subsequently, the present invention tested the concentration dependence and power dependence of the photothermal conversion of the nanoparticles. Figure 8 As shown in (d), (e), and (f), at 0.3 W cm -2 At the power of 100ugmL, the temperature of BTBT NPs solution gradually increased with the increase of concentration; -1At the concentration of 1.5 wt % BTBT NPs, the temperature of the BTBT NPs solution gradually increased with the increase of laser power. Through three cycles of laser on and off, it can be seen that the maximum temperature of the solution did not drop significantly, but the maximum temperature of the commercial photothermal reagent ICG gradually decreased. The above shows that BTBT NPs have excellent cyclic stability ( Figure 8 (e)). After testing and calculation, the photothermal conversion efficiency of BTBTNPs is 77.03% ( Figure 8 In order to further explore the reasons why BTBT NPs have better photothermal performance than the other two photosensitizers, the present invention first optimized the structures of the three photosensitizers in the singlet excited state, and then compared the angle changes between the three different donor structures and the intermediate acceptor structures. Fig. 9 As shown in the figure, BTBT experiences the largest dihedral angle change after light excitation, reaching 3.68°, which is larger than 3.22° of ATBT and 2.64° of NTBT, indicating that BTBT undergoes a stronger intramolecular rotation when returning to the ground state, thus facilitating photothermal conversion. The BTBT of the present invention can enhance photodynamics and promote photothermal conversion efficiency.
[0057] 6. In vivo imaging performance
[0058] BTBT NPs were injected into subcutaneous tumors of tumor-bearing mice via the tail vein to study their in vivo fluorescence imaging capabilities. Fig.10 As shown, the fluorescence signals of the tumor site of tumor-bearing mice were recorded at different time points (1, 2, 4, 8, 12, 18 and 24 h) after injection of BTBT NPs. As the incubation time of the nanoparticles in the mouse body gradually increased, the fluorescence intensity of the tumor site gradually increased. After 12 hours, the tumor site accumulated the most nanoparticles. Subsequently, the present invention explored the metabolism of BTBT NPs in mice. Fig.11 As shown in the figure, the fluorescence intensity of BTBT NPs in the blood gradually decreased, and almost no fluorescence was seen after 10 days. In addition, BTBT NPs mainly accumulated in the lungs, stomach, intestines and tumors. After 10 days, only a small amount of fluorescence was visible in the stomach and intestines. The above shows that BTBT NPs can be metabolized well and have good biosafety.
Claims
1. A photosensitizer for photodynamic and photothermal therapy guided by near-infrared fluorescence imaging, characterized in that: The structural formula is as follows:
2. The method for preparing a photosensitizer according to claim 1, characterized in that: The following steps are involved: (1) adding 4,8-bis(5-bromothiophen-2-yl)-6-(2-ethylhexyl)-[1,2,5]thiadiazole[3,4-F]benzotriazole, phenylboric acid, tetrakis(triphenylphosphine)palladium and potassium carbonate to a solvent; (2) reflux the mixed solution at 60-100° C. for 10-24 hours; (3) After the reaction is completed, the mixture is washed and the solvent is removed, followed by column chromatography purification.
3. The preparation method according to claim 2, characterized in that: The molar ratio of 4,8-di(5-bromothiophene-2-yl)-6-(2-ethylhexyl)-[1,2,5]thiadiazole[3,4-F]benzotriazole and phenylboronic acid added is 1:2-5.
4. The preparation method according to claim 2, characterized in that: The solvent is a mixed solvent of tetrahydrofuran and water.
5. Use of the photosensitizer according to claim 1 in preparing a tumor treatment preparation.
6. Use of the photosensitizer according to claim 1 in the preparation of a photodynamic and photothermal combined therapy preparation.
7. An integrated tumor diagnosis and treatment preparation, characterized in that: The photosensitizer according to claim 1.
Citation Information
Patent Citations
Infrared organic light-emitting material based on benzobisthiadiazole derivative
CN110872308A
Near-infrared two-region aggregation-induced emission fluorescent compound as well as preparation method and application thereof
CN113214293A
Organic compound capable of generating Raman spectrum signal and preparation thereof
CN115141213A
Compound for tumor targeted imaging and photodynamic therapy as well as synthesis method and application of compound
CN116425739A
